Prevention of severe intestinal infections, including cholera, does not lose its relevance due to episodic outbreaks. Creation of a new variant of the cholera vaccine based on a genetically modified non-toxigenic V. cholerae strain supplemented with a recombinant cholera toxin β subunit (CtxB) is a promising approach. The β subunit elicits an immune response but has no toxic effect without the ɑ subunit. The world experience in obtaining recombinant CtxB using bacterial cultures has been studied, approaches have been chosen for the production and purification of CtxB in the laboratory. The literature devoted to the peculiarities of the interaction of CtxB with intestinal epithelial cells was also analyzed [1]. Using standard molecular biological methods, a line of plasmids was obtained that allows random triggering of ctxB expression in E. coli cells. The constructed vectors differ in their encoded signal sequence fused to the gene of the target protein. When expression is activated, a chimeric polypeptide molecule containing CtxB and a fragment of the E. coli OmpA protein or Erwinia carotovora PelB protein is synthesized [2]. These sequences ensure the release of the produced toxin into the culture medium and make it possible to simplify the process of its purification.